Kidney Cancer Drugs Market Size, Share, Growth Analysis, By Type(Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma), By End user(Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35I2234 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 98 | Figures: 73

Kidney Cancer Drugs Market News

In January 2023, The FDA granted a speedy approval to pembrolizumab (Keytruda) plus axitinib (Inlyta) to be used in the treatment of adults that suffer from advanced renal cell carcinoma (RCC) and have progressed after prior treatment with a VEGF-targeted therapy.

In February 2023, The FDA granted a hastened approval to nivolumab (Opdivo) plus cabozantinib (Cabometyx) to be used in the treatment of adults who have advanced RCC and have progressed even after prior treatment with a VEGF-targeted therapy.

In March 2023, The FDA also granted a speedy approval to pembrolizumab plus lenvatinib (Lenvima) for the treatment of adults with advanced RCC who have progressed after prior treatment with a VEGF-targeted therapy.

In April 2023, The FDA granted a hurried approval to avelumab (Bavencio) plus axitinib (Inlyta) to be used in the treatment of adults with advanced RCC who have progressed even after prior treatment with a VEGF-targeted therapy.

Kidney Cancer Drugs Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Kidney Cancer Drugs Market size was valued at USD 4.64 Billion in 2023 and is poised to grow from USD 4.9 Billion in 2024 to USD 7.51 Billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

Fierce competition and continuous innovation rule the competitive landscape in the kidney cancer drugs market. A large number of pharmaceutical firms, emerging and established, are constantly engaged in R&D efforts to introduce novel therapies. By focusing on targeted therapies and precision medicine, these companies are putting in tremendous efforts to address the evolving needs of kidney cancer patients. Advancements in treatment modalities are being upscale thanks to partnerships between pharmaceutical firms and academic institutions. 'Pfizer Inc (US)', 'Aurobindo Pharma (India)', 'Bristol-Myers Squibb Company (US)', 'Sanofi (France)', 'Abbott (US)', 'Mylan N.V. (US)', 'Sun Pharmaceutical Industries Ltd (India)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Novartis AG (Switzerland)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Cipla Inc (India)', 'AstraZeneca (UK)', 'Fresenius SE & Co. KGaA (Germany)', 'Dr. Reddy's Laboratories Ltd (India)', 'Lupin (India)', 'Teva Pharmaceutical Industries Ltd (Israel)', 'Endo International plc (Ireland)'

Immunotherapy is a major driving force in the growth of the kidney cancer drugs market. This new innovative approach takes control of the body's immune system to target and attack cancer cells. Immunotherapy has shown successful results in treating kidney cancer as it improves the body's natural defenses, thus providing a ray of hope particularly in cases where traditional therapies have limited effect. Continuous research to unveil new combination treatments and immunotherapeutic agents are allowing patients access to less invasive and more effective alternatives, greatly increasing their chances of better outcomes in the battle against kidney cancer.

Personalized Treatment Paradigm: The recent shift towards personalized treatment approaches is a major key market trend in the kidney cancer drugs sector. The identification of specific biomarkers has been made possible due to advances in molecular diagnostics and genetic profiling, allowing the generation of tailored therapies that target individual patient characteristics that vary from patient to patient. This trend marks a huge development in kidney cancer care as it enhances the effectiveness of treatment while reducing side effects.

North America has held on to the rank of one of the most prominent regions in the global kidney cancer drugs market. A variety of factors including early adoption of advanced treatment options, well-established healthcare infrastructure, and a high prevalence of kidney cancer cases can be credited for this region’s dominance. Strong research and development initiatives that help introduce cutting-edge therapies into the market help the region retain its market share.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Kidney Cancer Drugs Market News

Kidney Cancer Drugs Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Kidney Cancer Drugs Market?

Who are the key vendors in the Kidney Cancer Drugs Market?

What is the key driver of Kidney Cancer Drugs Market?

What is the key market trend for Kidney Cancer Drugs Market?

Which region accounted for the largest share in Kidney Cancer Drugs Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300